Current biologic treatment options for RA and PsA comprise: anti-cytokine agents: tumor necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), interleukin-17 inhibitors (IL-17i) and interleukin-12/23 inhibitors (IL-12/23i). The gene discussed is TNF; the disease is rheumatoid arthritis.